A systematic review and meta-analysis revealed that the rate of locoregional control was worse in patients with ERBB2-positive tumors than luminal A tumors in breast cancer.38 As expected, tumor size was inversely associated with OS and RFS from the locoregional management. Here, ERBB2 is linked to breast carcinoma.